Mark Vandewalker, MD
Allergy · Columbia, MONPI 1386833358
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,425 of the $15,342 with a category attached, or 61.4%. 26 manufacturers reported payments, led by Boehringer Ingelheim at 40.0% of the total. Reporting peaked in 2019 at $11,675 and has fallen 94.0% since, to $698 in 2025.
Across 233 payments — averaging $65.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$6K
- Sunovion Pharmaceuticals Inc.$5K
- AstraZeneca$2K
- GSK$926
- Sanofi$399
- Genentech USA, Inc.$301
- plus $1K from 20 others
Across 358 payments — averaging $8226.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.4M
- Teva Pharmaceuticals USA, Inc.$512K
- Cipla USA Inc.$293K
- Hikma Pharmaceuticals USA$219K
- Chiesi USA, Inc.$198K
- GSK$172K
- plus $153K from 3 others
What the payments were for
- Consulting fees$1171%
- Speaking & faculty fees$9,42561%
- Travel & lodging$9876%
- Food & beverage$4,74731%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 15 | $6,134 |
| Sunovion Pharmaceuticals Inc. | 15 | $4,687 |
| AstraZeneca | 78 | $1,683 |
| GSK | 41 | $926 |
| Sanofi | 18 | $399 |
| Genentech USA, Inc. | 13 | $301 |
| Novartis | 15 | $291 |
| Grifols USA, LLC | 9 | $259 |
| Regeneron Healthcare Solutions, Inc. | 5 | $108 |
| Greer Laboratories, Inc. | 1 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Sanofi-aventis U.S. LLC | 1 | $55 |
| Alk-abello, Inc | 1 | $50 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $36 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Pharming Healthcare, Inc. | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Verona Pharma, Inc. | 1 | $21 |
| Biocryst US Sales Co., LLC | 1 | $20 |
| Pfizer | 1 | $18 |
| Amgen | 1 | $17 |
| Merck | 2 | $17 |
| Octapharma USA, Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Regeneron | 1 | $15 |
| Optinose US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LONHALA MAGNAIR$4,432
- NUCALA$233
- Prolastin-C$136
- TRELEGY ELLIPTA$125
- AIRSUPRA$110
- DUPIXENT$104
- FASENRA$103
How this compares
Too few allergy providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 12 | $52,470 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $42,027 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $18,856 |
| Epinephrine | 60 | $12,347 |
| Spiriva RespimatTiotropium Bromide | 14 | $9,079 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,095 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $4,362 |
| Montelukast Sodium | 224 | $1,776 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $769 |
| Fluticasone Propionate | 16 | $461 |
| Levocetirizine Dihydrochloride | 39 | $443 |
| Azelastine Hcl | 13 | $140 |
| Prednisone | 12 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $926 | $50,12285 claims |
| AstraZenecaBreztri Aerosphere | $1,683 | $18,85630 claims |
| Boehringer IngelheimSpiriva Respimat | $6,134 | $9,07914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Missourion file to place this against a meaningful peer group, so we don't.
Other allergy in Columbia
- William StrickerColumbia$4K
- Maria SabioKirkwood$15K
- Silvia HuebnerSpringfield$14K
- Josie VitaleSaint Louis$10K
- Jeffrey WrightSaint Louis$7K
- Lawrence LandwehrWarrensburg$6K
- Laura EssweinSaint Louis$6K
- Sanchayita TripathyRolla$5K
- Robert OnderSaint Louis$4K
- Douglas BersonChesterfield$929
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.